Drug, bio-affecting and body treating compositions inventions 02/06

20060040852 - Il-1 antagonist formulations: Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID...

20060040853 - Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras: The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis...

20060040851 - Topical compositions for the treatment, protection and restoration of skin and connective tissues: The invention relates to uses of GAG-peptide complexes and polypeptides obtained from connective tissue albeit indirectly which are substantially free of DNA for the treatment, protection and restoration of skin and connective tissues. The invention provides a topical composition comprising at least on GAG-peptide complex comprising two or three GAG-chains....

20060040850 - Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differenti: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous...

20060040854 - Prostate hyperplasia therapy: The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity....

20060040856 - Glycopegylated factor ix: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a...

20060040855 - Low efficacy gonadotropin agonists and antagonists: The present invention provides glycoprotein hormone analogs having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide. The analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond. The present invention also provides a method for stimulating fertility...

20060040857 - 1-desamino-8-a-arginyl vasopressin analogs: e

20060040858 - Novel peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also...

20060040864 - Apparatus and method for transdermal delivery of vascular endothelial growth factors: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or assembly) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In...

20060040860 - Intra-tracheal application of vascular endothelial growth factor (vegf) for the prevention of lung damages caused by hperoxia: The invention relates to the field of pulmonary diseases that are related to oxygen provision that is higher than physiological (hyperoxia) and to the use of vascular endothelial growth factor (VEGF) for treatment and prevention. Hyperoxic exposure causes a direct cellular damage in the lung and disturbs lung development. The...

20060040861 - Method of treating, preventing, and diagnosing prostate cancer: A method of treating prostate cancer in a prostate cancer patient is disclosed. In one embodiment of the present invention, the method comprises the step of decreasing or blocking the patient's leptin interaction with leptin receptor or increasing adiponectin interaction with adiponectin receptors....

20060040863 - Methods for treatment of diabetes using peptide analogues of insulin: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered...

20060040859 - Peptides, dnas, rnas, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same: Pharmaceutical compositions containing adrenomedullin antagonist peptides, DNA, RNA compounds inhibitory on adrenomedullin activity, resulting in the efficient blockade of the induction of macroangiogenesis or vasculogenesis of more than 8 μm (in case of murine models), suppress the proliferation of cancer cells due to that inhibitory effect and suppress the protective...

20060040865 - Platelet production promoting agent: The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a...

20060040862 - Xaf genes and polypeptides: methods and reagents for modulating apoptosis: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis....

20060040866 - Peptides and compounds that bind to a receptor: Peptides and compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed....

20060040867 - Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections: A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound...

20060040868 - Methods for treating premature infants: Methods of treating premature infants include administering, to an infant, an agent that increases the blood or tissue levels, production, function, or activity of hCG, LH, FSH, GnRH, or activin or that decreases the blood or tissue levels, production, function, or activity of follistatin and inhibin....

20060040870 - Enhancement of apoptosis by caspase-9 inhibitors: The present invention provides methods for inducing apoptosis in a tumor cell by contacting the cell with a caspase-9 inhibitor....

20060040869 - Pharmaceutically useful compounds: A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1-4 carbon atoms; when X is —NR4R5, R2 is...

20060040871 - Bacterial transforming agent: A method of increasing the sensitivity of a bacterial strain to a cell-wall active antimicrobial agent, to which the bacterial strain or a progenitor strain from which the bacterial strain has evolved is sensitive is described. The method comprises the step of exposing said bacterial strain to a transforming agent...

20060040872 - Calcium channel inhibitor: The present invention relates to an agent which inhibits or suppresses calcium channel where dipeptide Val-Tyr (VY) or a substance containing the same is an effective ingredient. Examples of the substance containing VY are hydrolysate (sardine peptide) of fish meat of sardine, etc., and VY or VY-containing substance is also...

20060040873 - Composition for use in prophylaxis and or treatment: The present invention relates generally to a composition for use in the prophylaxis and/or treatment of pain. More particularly, the present invention relates to a composition for use in the prophylaxis and/or treatment of chronic neuromuscular pain. The composition of the present invention is particularly useful in the prophylaxis and/or...

20060040874 - Process for the preparation of topiramate: The present invention relates to a process for the preparation of topiramate, intermediates in this process and a process for the preparation of these intermediates....

20060040875 - Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b): A UGT2B inhibitor capable of increasing the bio-availability of a drug, being a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol,...

20060040876 - Modulation of peroxisome proliferator-activated receptors: A method of treating a peroxisome proliferators-activated receptors related disease by administering to a subject in need thereof an effective amount of a modulator of 15-keto prostaglandin-Δ13-reductase. Also disclosed are methods of identifying a compound for inhibiting activity of the reductase and of lowering blood glucose levels by administering to...

20060040877 - Novel spinosyn-producing polyketide synthases: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns....

20060040884 - Antisense oligonucleotides directed to genes regulated by trapoxin-induced hdac inhibition: Antisense compounds, compositions and methods are provided for modulating the expression of trapoxin A regulated genes, including but not limited to those genes induced by ectopic expression of p21waf1 that are disclosed herein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding these genes. Methods of...

20060040878 - Bacterial antigen induced bone morphogenesis: Bone growth following a spinal fusion procedure is enhanced by packing the fusion site with a mixture of a bone material such as allograft or autograft, and an antigen produced from bacteria or parasitic organisms. A composition for inducing bone morphogenesis also is disclosed....

20060040885 - Bioprosthetic heart valves: The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration,...

20060040879 - Chloroquine coupled nucleic acids and methods for their synthesis: This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount...

20060040886 - Compositions and methods for treatment of prostate and other cancers: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for...

20060040882 - Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells: Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference...

20060040880 - Methods and compositions for treating neuropathic pain: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention...

20060040883 - Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna: This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such...

20060040881 - Modulators of coagulation factors: The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass....

20060040887 - Method for stimulating the immune, inflammatory or neuroprotective response: Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective...

20060040889 - 2-polycyclic propynyl adenosine analogs having a2a agonist activity: c

20060040888 - 2-propynyl adenosine analogs with modifed 5'-ribose groups having a2a agonist activity:

20060040890 - Anti-viral nucleosides: 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process....

20060040895 - Aesthetic use of hyaluronan: A method to rejuvenate tissue by injection of a solution containing between about 0.5% and about 10% hyaluronic acid is described. The application of the solution to tissue regions having wrinkles, line, creases, abnormalities and the like is effective in diminishing the signs of aging....

20060040894 - Compositions and methods using hyaluronic acid: Compositions and devices including hyaluronic acid and a compound that inhibits degradation of hyaluronic acid, and methods of making and using same....

20060040893 - Immunomodulatory methods using oligosaccharides: Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper...

20060040891 - Lipid a and other carbohydrate ligand analogs: The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of...

20060040892 - Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles: A method for synthesizing uniformly sized hyaluronic acid (“HA”) particles that are substantially free from oil and surfactant contaminants. The method comprises crosslinking HA chains with 1-ethyl-3-(3-dimethlyaminopropyl) carbodiimide hydrochloride (“EDAC”) and adipic acid dihydrazide in a water/acetone mixture....

20060040896 - Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity: A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously,...

20060040897 - Compositions for treating and/or preventing diseases characterized by the presence of metal ions: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some...

20060040898 - Novel boronate esters: The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin....

20060040899 - Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies: e

20060040900 - R(-)-11-hydroxyaporphine derivatives and uses thereof: The invention features derivatives of R(—)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith....

20060040901 - Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants: The present invention discloses new cyclic glycerophosphates and cyclic popandiol phosphates and pharmaceutical compositions comprising said compounds for promoting neural activity such as neuronal outgrowth, nerve growth, prevention of nerve degeneration and nerve rescue....

20060040902 - Compunds useful as pesticides: Compounds useful to control pests are provided....

20060040903 - Methods of use related to xerostomia: The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and...

20060040904 - Vaginal cream compositions, kits thereof and methods of using thereof: The present invention is directed to pharmaceutical vaginal cream compositions comprising a conjugated estrogen and a stabilizer. The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated...

20060040905 - Formulation of nefopam and its use in the treatment of pain: (+)-Nefopam is formulated for intranasal administration, for use in the treatment of pain....

20060040910 - Macrocycles useful in the treatment of alzheimer's disease: for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods...

20060040911 - Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus): A method for treating and/or preventing the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered thereto an effective amount of bioflavonoids extract derived from fructus crataegus such as; rutin, quercetin, kaempferol and vitexin or a mixture thereof....

20060040908 - Novel chalcogenoxanthylium dyes for purging blood pathogens and for photodynamic therapy: Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds....

20060040906 - Piperazine urea derivatives as melanocortin-4 receptor agonists: Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes....

20060040909 - Selenophene compounds: In formula (I), each of R1 and R2, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, heteroaryl, or C(O)Ra; X is Se, S, O, or NRb; and each of R3, R4, R5, and R6, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; in which...

20060040907 - Triptolide analogs for the treatment of autoimmune and inflammatory disorders: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds....

20060040912 - Compounds for pdt: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or...

20060040914 - Meso-substituted porphyrins: Meso-substituted porphyrins of general formula (I) suitable for the use as photosensitising agents, in particular in photodynamnic therapy, are herein described....

20060040913 - Porphyrins and related compounds: New porphyrins and chlorins including bacteriochlorins, for photodynamic therapy....

20060040915 - Process for the preparation of cefdinir: The present invention relates to a process for the preparation of cefdinir on an industrial scale....

20060040916 - Carbapenem compound crystals and injection preparations: The present invention provides carbapenem hydrochloride trihydrate crystals, which are chemically stable, easily purified and useful as antimicrobial agents, a process for producing them, and a powdery charged preparation for injection containing them. That is, it provides carbapenem hydrochloride trihydrate crystals having a powdery X-ray diffraction pattern containing lattice distances...

20060040917 - Benzoxazepine derivatives as selective estrogen receptor modulators: The present invention is directed to novel benzoxazepine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor....

20060040918 - Benzo d!azepine derivatives for the treatment of neurological disorders: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders....

20060040919 - Bronchorelaxing compounds: wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl,...

20060040922 - Aripiprazole, olanzapine and haloperidol pamoate salts: The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio...

20060040920 - Crystal forms of olanzapine and processes for their preparation: The invention relates to a process for the preparation of form I of olanzapine, crystallized from a solvent mixture which comprises 2-propanol, some pseudopolymorphic forms, namely solvates of olanzapine, anew polymorphic form A of olanzapine, and processes for the preparation thereof....

20060040921 - Process and intermediates for the preparation of olanzapine: The invention provides an improved process for preparing Olanzapine as well as intermediates therefor....

20060040923 - Benzodiazepine derivatives and pharmaceutical compositions containing them: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; —each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio,...

20060040924 - Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic: The present invention refers to the use of derivatives of aryl (or heteroaryl) azolylcarbinols of general formula (I), and their physiologically acceptable salts, as medicinal products for human and/or animal therapeutics for the treatment of renal colic....

20060040925 - Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity: Cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man....

20060040926 - Fluorescent fused-ring triazoles that inhibit cell proliferation and uses thereof: Fused-ring triazole compounds which inhibit proliferation of cells and exhibit a unique and intense fluorescence are provided. Also provided are methods for synthesizing these compounds and methods for using these compounds to inhibit cell proliferation and infection and to label and fluorescently detect selected molecules....

20060040927 - Heterocyclic antiviral compounds: Compounds having the formula I wherein A, m and R1 are herein defined are Hepatitis C virus polymerase inhibitors. Also disclosed are compositions and methods for treating diseases mediated by HCV and for inhibiting hepatitis replication. Also disclosed are processes for making the compounds and synthetic intermediates used in the...

20060040928 - Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds: m

20060040929 - (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1h)-thione and method of preparation thereof:

20060040930 - Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same:

20060040931 - Benzomorpholine derivatives:

20060040933 - Nonsteroidal antiinflammatory agents: are useful in the treatment of inflammation....

20060040932 - Stable crystalline form of bifeprunox mesylate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethanesulfonate): The invention relates to a stable polymorphic form of the compound 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate (INNM bifeprunox mesylate), a method for the preparation of said polymorphic form and its use in pharmaceutical products, especially in pharmaceutical products for the treatment of psychotic disorders and Parkinson's disease....

20060040934 - Use of stat-6 inhibitors as therapeutic agents: The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments....

20060040935 - Method of treating impotence due to spinal cord injury: A class of cGMP PDE inhibitors, including sidenafil and pharmaceutically acceptable salts thereof, which can be used to treat sexual dysfunction in male and female animals, especially humans, with a spinal cord injury. The invention can be used to treat sexual dysfunction in male animals that exhibit essentially no residual...

20060040936 - Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors: c

20060040937 - N-aroyl cyclic amines as orexin receptor antagonists: This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals....

20060040938 - Substituted fullerene compositions and their use as antioxidants: i

20060040939 - Benzamide inhibitors of the p2x, receptor:

20060040943 - 3-furanyl analogs of toxoflavine as kinase inhibitors: the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R1 represents C1-4alkyl, C1-4alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C1-4alkyloxycarbonyl; R2 represents hydrogen or...

20060040944 - 5-aza-7-deazapurine derivatives for treating flaviviridae: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and...

20060040942 - 5-ethylimidarotriazones: The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases....

20060040941 - 7-aminoimidazotriazones: The invention relates to novel 7-amino-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases....

20060040940 - Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands: The present invention provides a pharmaceutical composition providing a compound of formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable excipient: (I), in which: X and Y independently represent CH or N, with the proviso that if X is CH then Y is also CH; R1 represents...

20060040945 - Annellated pyrrole compounds as proton pump inhibitors for treating ulcer: Inhibiting gastric proton pump in a mammal is accomplished by the use of a compound of formula (1) wherein the variables have the meaning given in the present description. A preferred compound of formula (2) is this treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or lesions...

20060040946 - Methods and compositions for the treatment of metabolic disorders: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated....

20060040947 - Amino-heterocycles as vr-1 antagonists for treating pain: the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than two, of W, X and Y...

20060040948 - Macrocyclic beta-secretase inhibitors: R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering...

20060040949 - Novel compounds with antibacterial activity: The present invention describes novel anti-bacterial compounds of formula (I)....

20060040950 - Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists: This invention concerns substituted I-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of schizophrenia, anxiety, depression, emesis and IBS. The...

20060040951 - Use of 5-ht2 receptor antagonists for the treatment of sleep disorders: The invention relates to the use of 5-HT2 receptor antagonists for the preparation of a medicament for extending both non-REM sleep an REM sleep....

20060040953 - Diketopiperazine salts for drug delivery and related methods: Biologically active agent delivery compositions, which comprise diketopiperazine carboxylate salts are provided. Related methods for making and using the biologically active agent delivery compositions are also provided....

20060040952 - Il-8 receptor antagonists: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20060040954 - Soluble amide & ester pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers....

20060040955 - 4-pyrimidineamine compounds and their uses as anti-proliferative agents: The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers....

20060040956 - Substituted alkylamine derivatives and methods of use: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject...

20060040957 - Bicyclic pyrimidine matrix metalloproteinase inhibitors: l

20060040958 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060040959 - Adenosine a3 receptor modulators: wherein R, R2, R3 and A have the meanings given in the specification, are endowed with selective A3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A3 receptor, or can be used in a diagnostic application...

20060040961 - Furanopyrimidines: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial...

20060040960 - Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders: This invention relates to a compound of Formula (I) wherein Y is CH or N; Ar1 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each selected independently from (C1-C3)alkoxy halo, OH, CF3, CN, NO2 and (C1-C3)alkyl, said alkyl being optionally substituted with CF3; Ar2 is phenyl...

20060040962 - Pharmaceutical formulations: Disclosed are pharmaceutically acceptable PDE V inhibitor Formulations that are especially useful for treating male erectile and female sexual dysfunction and other physiological disorders....

20060040963 - Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to...

20060040964 - Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines: Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric...

20060040965 - Pyrrolo[2,3-d]pyrimidines that modulate ack1 activity: b

20060040966 - Substituted aryl-amine derivatives and methods of use: wherein R, R1 and R2 for each formula are defined herein. The invention further includes analogs, prodrugs and pharmaceutically acceptable salts and derivatives of Formulas I and II, as well as pharmaceutical compositions, medicaments and methods thereof for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer...

20060040967 - Pyrimidine derivative as selelctive cox-2 inhibitors: e

20060040968 - 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:...

20060040969 - Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular...

20060040970 - Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group: (wherein R1 is methyl, cyclopropylmethyl or the like; R2 and R3 are hydroxy, methoxy, acetoxy or the like; both Y and Z are valence bonds, —C(═O)— or the like; X is C2-C5 carbon chain (one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen) constituting a part...

20060040971 - Rapamycin polymorphs and uses thereof: The present invention provides rapamycin polymorph Form II. This invention also provides processes for preparing rapamycin polymorph Form II and pharmaceutical compositions including rapamycin polymorph Form II....

20060040972 - Pyrazolonaphthyridine derivative: wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and...

20060040973 - Novel guanidine mimics as factor xa inhibitors: e

20060040974 - Retroviral protease inhibitors: HIV protease inhibitors are disclosed which are characterized as having both hydroxyethylamine and N-heterocyclic moieties....

20060040975 - Fused ring nk1 antagonists: V

20060040976 - Thiobenzimidazole derivatives:

20060040979 - 3-aryl-2-hydroxypropionic acid derivative i: A novel 3-aryl-2-hydroxypropionic acid derivative, a process and intermediate for its manufacture, pharmaceutical preparations containing it and the use of the compound in clinical conditions associated with insulin resistance....

20060040978 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is...

20060040977 - 5-ht7 receptor ligands: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline propyl sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is...

20060040980 - Ionophores as cancer chemotherapeutic agents: This invention relates to anti-cancer uses of ionophores of which clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) is a prototype drug. The present invention is further directed toward using ionophores such as clioquinol alone, or in combination with metals (e.g., zinc or copper, manganese) as anti-cancer and anti-angiogenic agents. This invention further relates to the...

20060040981 - Use of phosphodiesterase-4 inhibitors as enhancers of cognition: The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a...

20060040982 - 2-substituted quinoline compounds and their uses: The present disclosure provides 2-substituted-quinoline compounds that inhibit the IgE receptor signaling cascade that leads to the release of chemical mediators, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and/or prevention of...

20060040983 - Quinolinyl-pyrrolopyrazoles: A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound....

20060040984 - Novel piperidine derivatives for use in the treatment of chemokine medicated disease states: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state....

20060040985 - Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient: wherein A is a group represented by L-W [wherein L is a bond or CH2; and W is O, SOn (wherein n is 0 to 2), or —NR7— (wherein R7 is hydrogen or lower alkyl)]; each of G1 and G2 is (CH2)r (wherein r is 0 to 2), provided that...

20060040986 - Erythropoietin production accelerator: R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof....

20060040987 - Ultrashort-acting opioids for transdermal application: The subject invention concerns novel analogs of fentanyl opioids. The subject invention also concerns methods for synthesizing the compounds of the invention. The invention also concerns methods for treating pain in a patient by administering a compound of the invention to a person in need of such treatment....

20060040988 - Cox-2 inhibiting pyridine derivatives: e

20060040989 - N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion:

20060040990 - Epothilone derivatives, process for their production, and their pharmaceutical use:

20060040991 - Pharmaceutical presentation form for oral administration of a poorly soluble active compound, process for its preparation and kit: The invention relates to a pharmaceutical presentation form for the oral administration of indibulin in the form of an aqueous drink solution, and a method for its preparation....

20060040993 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt: Disclosed are 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salts, or solvates thereof; processes for preparing such compounds, compositions comprising such compounds and the use of such compounds in medicine....

20060040992 - Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines: There are provided novel compounds of formula (I) wherein T, X, Y and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric...

20060040994 - Substituted amide beta secretase inhibitors: R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering...

20060040995 - Method for preparing hydroxypicolinic scid derivatives: The invention concerns a method for preparing compounds of general formula (I) wherein: n, Q1, Q2, X1, X2, Y and Z are as defined in the description....

20060040996 - Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer...

20060040997 - Benzthiazole-3 oxides useful for the treatment of proliferative disorders: e

20060040998 - Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof:

20060040999 - Cetp inhibitors: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring...

20060041000 - 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase: 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and analogues useful as inhibitors of macrophage elastase are disclosed....

20060041001 - Novel imidazolic compounds, method for preparing same and use thereif as medicines: wherein R1 is hydrogen, fluoro or methoxyl, R1 being in position 2, 3, 4 or 5 of the aromatic carbocycle; R2 is hydrogen or methyl; R3 is hydrogen, methyl or ethyl; and their pharmaceutically acceptable acid addition salts, hydrates of their pharmaceutically acceptable acid addition salts as well as the...

20060041002 - Guanylhydrazone compounds, compositions, methods of making and using: e

20060041003 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone...

20060041004 - Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4h-carbazol-4-one and ondansetron therefrom: The present invention provides a rapid, high-yielding process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one without using a secondary amine as a catalyst, and without using glacial acetic acid as a solvent. The present invention further provides a rapid, high-yielding process for preparing ondansetron from 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one without using alumina as a catalyst....

20060041005 - Process for the synthesis c-2, c-3 substituted n-alkylated indoles useful as cpla2 inhibitors: e

20060041006 - Pde4b inhibitors and uses therefor: Compounds active on phosphodiesterase PDE4B are provided. Also provided herewith are compositions useful for treatment of PDE4B-mediated diseases or conditions, and methods for the use thereof....

20060041007 - Metastable benzoxepne derivatives which can be used in the treatment of dyslipidaemia a therosclerosis and diabetes, pharmaceutical compositions comprising them and processes for the preparation thereof: The present invention relates to novel metastable derivatives of benzoxepines of the formula (I) in which n represents 0, 1 or 2; and the radicals R, which may be identical or different, are alkyl or alkoxy groups, or halogen atoms, which can be used in the treatment of dyslipidaemia, atherosclerosis...

20060041008 - Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders: The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders....

20060041009 - Pharmaceutical compound containing silymarin and carbopol, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus: The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (β cells). It therefore regulates the serum levels of...

20060041010 - (-)-epigallocatechin gallate derivatives for inhibiting proteasome: (−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R1 is selected from the group of —H and C1 to C6 acyl group; R2, R3, and...

20060041011 - Prodrugs of propofol, compositions and uses thereof: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting....

20060041012 - Cis-diiodo-(trans-l-1,2-cyclohexanediamine) platinum (ii) complex and processes for preparing high purity oxaliplatin: The present invention is related to pure cis-diiodo-(trans-L-1,2-cyclohexanediamine) Pt (II) complex, and a process of its preparation. The present invention is further related to the preparation of oxaliplatin using said cis-diiodo-(trans-L-1,2-cyclohexanediamine) Pt (II) complex....

20060041013 - Alanosine formulations and methods of use: Stable liquid formulations of the anti-tumor agent L-alanosine are described. These formulations preferably comprise L-alanosine in an aqueous environment having a basic pH, preferably in the range of about pH 8-9. The alanosine formulations and compositions disclosed herein can be used for various purposes, including the treatment of various cancers,...

20060041014 - Treatment of male sexual dysfunction: The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED....

20060041015 - Use of treosulfan and derivaties thereof for treating multiple sclerosis: The invention relates to the use of treosulfan and/or derivatives thereof for producing a pharmaceutical composition used in the treatment of multiple sclerosis....

20060041016 - Composition and method for the treatment of psoriasis: The use of a prostaglandin A2 derivative, and prodrugs of the compound, for the manufacture of a medicament for the treatment and/or alleviation of psoriasis is presented, as well as a method of treatment, involving the topical application of such prostaglandins. Compositions containing a therapeutically active, and physiologically acceptable amount...

20060041018 - Method of monitoring/controlling thysanoptera: e

20060041017 - Synergistic conjugated linoleic acid (cla) and carnitine combination: The present invention relates to the unexpected discovery that a combination of effective amounts of carnitine (in any form, as described in further detail herein) and conjugated linoleic acid (CLA) administered to a patient in need thereof exhibits synergistic activity in treating obesity by reducing fat mass and overall weight...

20060041019 - Inhibitor of anticancer drug side effect: An object of the present invention is to provide a novel agent for suppressing side effects of an antitumor agent, which can suppress side effects caused by the use of an antitumor agent, such as hair loss. The present invention provides an agent for suppressing side effects of an antitumor...

20060041020 - Novel cyclohexyl sulphones:

20060041021 - Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists: Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health,...

20060041022 - Treatment of amyotrophic lateral sclerosis with nimesulide: The present invention relates to methods for delaying the onset or progression of motor impairment associated with amyotrophic lateral sclerosis in a subject by administering to the subject a therapeutically effective amount of nimesulide. It further provides for a means of detecting and monitoring the progression of amyotrophic lateral sclerosis...

20060041023 - Facially amphilic polymers and oligomers and uses thereof: The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions....

20060041024 - Polycationic compounds and uses thereof: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally,...

20060041025 - Diphenyl ether antimicrobial compounds: wherein A1, A3, A6, and A8 independently represent CH or N; A2 represents N or C—X1a—R1; A4 represents N or C—X2b—R2; R1 and R2 independently represent H, or a hydrocarbon containing a minimum of one carbon atom and a maximum of twenty six carbon atoms, wherein the hydrocarbon is unsubstituted,...

20060035809 - Apoptosis-mimicking natural vesicles and use thereof in medical treatment: Natural biological vesicles with membranes which have lost phospholipid symmetry, especially those presenting phosphatidyl serine on outer membrane surfaces, such as red cell ghosts, are administered to mammalian patients, in immune system modifying amounts, for treatment or prophylaxis of inflammatory cytokine-related disorders, including autoimmune disorders, neurodegenerative disorders and endothelial dysfunction...

20060035810 - Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto: Provided is a method of increasing 3,4,5,6-tetrakisphosphate by increasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase, and a method of decreasing 3,4,5,6-tetrakisphosphate by decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase. A method of reducing salt, fluid or mucous secretion in a subject, comprising increasing the activity of inositol 1,3,4,5,6...

20060035811 - Methods of treating dry eye disease with lantibiotics: The treatment of dry eye disease with lantibiotics such as duramycin is described, along with pharmaceutical formulations useful for carrying out such treatments....

20060035812 - Neuroprotective dietary supplement: The invention relates to a novel dietary supplement mixture having improved neuroprotective activity and preventing, ameliorating or counteracting neurodegeneration and preventing, counteracting and/or improving cognitive function decline. It also provides a dietary supplement, which is to be administered in an oral dosage form....

20060035813 - Methods and formulations comprising agonists and antagonists of nuclear hormone receptors: Novel compounds, pharmaceutical compositions, and methods are provided for modulating processes mediated by nuclear hormone receptors. A partial or complete agonist or antagonist modulates, directly or indirectly, an activity of one or more nuclear hormone receptors for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs),...

20060035815 - Pharmaceutical compositions for delivery of ribonucleic acid to a cell: What is disclosed is a pharmaceutical composition for administration of a double stranded ribonucleic acid (dsRNA) molecule to an animal, comprising the dsRNA molecule and a peptide, wherein the dsRNA molecule comprises about 10 to about 40 base pairs, wherein the peptide comprises about 5 to about 40 amino acids...

20060035814 - Reagents and methods for smooth muscle therapies: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration....

20060035816 - Method and composition for inhibiting or slowing blood coagulation: A method and composition for inhibiting or slowing blood coagulation includes lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin....

20060035818 - Use of corticotroph-derived glycoprotein hormone to induce lipolysis: The use of corticotroph-derived glycoprotein hormone (CGH) to induce lipolysis, treat obesity, insulin resistance, and type II diabetes is described....

20060035817 - Use of galectin-3 and galectin-7 to promote the re-epithelialization of wounds: Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3...

20060035820 - New derivatives of echinocandine, their preparation process and their use as antifungals: t

20060035819 - Novel molecule: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the...

20060035821 - Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases: Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions....

20060035822 - Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases: Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions....

20060035825 - Alpha 5 beta 1 and its ability to regulate the cell survival pathway: The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma,...

20060035830 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliamy, urethral, esophageal, and tracheal/bronchial obstructions....

20060035831 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060035832 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060035833 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060035829 - Chemokine combinations to mobilize progenitor/stem cells: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 in combination with the CXCR2 chemokine GROβ, including its modified forms, are disclosed....

20060035834 - Compositions and methods for diagnosing and treating an inflammation: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in...

20060035827 - Compositions and methods for the treatment or prevention of gallbladder disease: Compositions and methods for the treatment or prevention of gallbladder disease are provided. In particular, pharmaceutical compositions containing an amount of serine proteinase inhibitor such as potato proteinase inhibitor II effective to induce gallbladder contraction in a host are provided. The compositions can be administered to individuals having a body...

20060035828 - Direct activation of atiii in whole blood and plasma and uses thereof: Methods of activating ATIII in situ in a blood product are disclosed, as is the use of such methods and blood products in treating infectious diseases, inflammatory disorders and diseases or conditions that are mediated by thrombin activation....

20060035823 - Isolated fragments of p62 nucleoporin and uses thereof: The invention is directed to isolated protein fragments of p62 nucleoporin including deletion isoforms and nucleic acid sequences encoding these deletion isoforms. The isolated deletion isoforms disclosed herein include the sequences: SEQ. ID NO.:1 MSGFNFGGTG APTGGFTFGT AKTATTTPAT GFSFSTSGTG GFNFGAPFQP ATSTPSTGLF SLATQTPATQ TTGFTFGTAT LASGGTGFSL GIGASKLNLS NTAATPAMAN PSGFGLGSSN LTNAISSTVT SSQGTAPTGF VFGPSTTSVA PATTSGGFSF...

20060035835 - Novel protein, production and use thereof: The present invention relates to a novel SSD (sterol-sensing domain)-containing protein derived from human liver, human testis and human brain, or a salt thereof, and a DNA encoding the same. Studies on the tissue-specificity of the protein expression, the expression change depending the intracellular cholesterol level, production of the transformant,...

20060035826 - Promotion of axonal regeneration: The present invention concerns a method of promoting axonal regeneration. In particular, the invention concerns a method of promoting the growth or regeneration of neurons, and treating disease or conditions associated with the loss, loss of function or dysfunction of nerve cells, in particular thalamic nerve cells, by administering a...

20060035836 - Treatment of acute coronary syndrome with an exendin: The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as...

20060035824 - Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation: The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass...

20060035837 - Compounds that inhibit hsp90 protein-protein interactions with iap proteins: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds....

20060035838 - Drug therapy for celiac sprue: A ministering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten....

20060035839 - Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments: The invention relates to a multimeric molecule which can imitate a natural multimeric proteinaceous ligand. The invention also relates to a multimeric molecule as defined above which is characterised in that it has the following general formula: A-Xn, wherein: n is equal to 3, 4, 5 or 6; A denotes...

20060035841 - D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture: e

20060035840 - Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof: wherein X1 represents Nor CR1; X2 represents Nor CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a...

20060035842 - Ophthalmic composition: It is an object of the present invention to provide an ophthalmic composition, wherein: the ophthalmic composition assures a sufficiently high degree of safety to eyes of the lens wearer; the ophthalmic composition reduces symptoms such as an unpleasant feeling or dryness of the eyes; the ophthalmic composition does not...

20060035843 - Tanaproget derivatives, metabolites,and uses thereof: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided....

20060035844 - Preventive or remedy for diseases caused by hyperglycemia: The present invention provides pharmaceutical compositions comprising as an active ingredient a selective SGLT1 inhibitor (e.g., an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect), which have a wider range of inhibitory effect on carbohydrate absorption and a hypoglycemic effect caused by fructose ingestion at regular diets and...

20060035845 - Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract: wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, T represents an anti-inflammatory subunit that can be a steroid or nonsteroid (nonsteroidal moiety) derived from a non-steroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID) and L represents a linker covalently linking M and T....

20060035847 - Glucopyranosyloxyprazole derivatives and use thereof in medicines: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo (lower alkyl) group or a halogen...

20060035846 - Preventing/correcting functional disorders of the pilosebaceous unit of mammals: Orally administratable cosmetic compositions, notably formulated as food supplements, useful for the prevention and/or treatment of functional disorders of the pilosebaceous structural unit of mammals, in particular by combating the cutaneous activation of the androgens over time, and especially for the treatment of oily and/or hyper-seborrheic skin and/or scalp, thin...

20060035848 - Broad-spectrum inhibitor of viruses in the flaviviridae family: The present invention relates generally to the fields of chemistry and molecular biology. More particularly, it concerns the use of compounds to treat viral infection. In a preferred embodiment, 2-amino-8-(β-D-ribofuranosyl) imidazo [1,2-a]-s-triazine-4-one may be used to treat infection by viruses of the Flaviviridae family....

20060035854 - Compositions and methods for coating medical devices: The present invention provides compositions and methods for coating medical devices with pharmaceutical agents and devices coated with the compositions. The coated devices provide controlled or sustained release of pharmaceutical agents for the treatment of wounds or disease....

20060035852 - Genetic products differentially expressed in tumors and the use thereof: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. Said invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which...

20060035849 - Methods and composition for modulating type i muscle formation using pgc-1 alpha: The invention provides novel methods and compositions for modulating type I muscle formation through modulation of PGC-1α activity or expression. Also provided are methods for identifying compounds that modulate type I muscle formation through modulation of PGC-1α activity or expression. Further provided are methods for treating disorders associated with type...

20060035857 - Methods and compositions for the diagnosis and treatment of cancer: Methods for the treatment of squamous cell carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities....

20060035858 - Methods for modulating lipoprotein and cholesterol levels in humans: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided....

20060035853 - Methods for tailoring the immune response to an antigen or immunogen: The invention relates to methods and reagents for immunizing animals to elicit specific cellular and humoral immune-responses against specific antigens, such as viral antigens, including HBsAg antigen. The invention provides methods of using specifically prepared immunogen in fresh or lyophilized liposome, proper routes of administration of the immunogen, proper doses...

20060035850 - Plant thymidine kinases and their use: This invention relates to novel plant thymidine kinases and their use in gene therapy. More specifically the invention provides novel thymidine kinases derived from tomato, pine, rice or thale cress. In further aspects the invention provides novel polynucleotides encoding the plant thymidine kinases, vector constructs comprising the polynucleotide, host cells...

20060035855 - Purified polypeptides having il-13 receptor activity: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4....

20060035856 - Purified polypeptides having il-13 receptor activity: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor α and/or IL13 receptor β and uses thereof....

20060035859 - Treating severe and acute viral infections: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin.